TEVA-ZOLMITRIPTAN TABLET
国家: 加拿大
语言: 英文
来源: Health Canada
产品特点
(SPC)
06-04-2020
该产品的某些文档当前不可用，您可以向我们的客户服务发送请求，我们将在获得它们后尽快通知您。
发送请求。
发送请求。
有效成分:
ZOLMITRIPTAN
可用日期:
TEVA CANADA LIMITED
ATC代码:
N02CC03
INN（国际名称）:
ZOLMITRIPTAN
剂量:
2.5MG
药物剂型:
TABLET
组成:
ZOLMITRIPTAN 2.5MG
给药途径:
ORAL
每包单位数:
3/6/50
处方类型:
Prescription
治疗领域:
SELECTIVE SEROTONIN AGONISTS
產品總結:
Active ingredient group (AIG) number: 0134381001; AHFS:
授权状态:
APPROVED
授权日期:
2011-06-07
产品特点
PRODUCT MONOGRAPH
PR
TEVA-ZOLMITRIPTAN
(zolmitriptan) tablets
2.5 mg
PR
TEVA-ZOLMITRIPTAN OD
(zolmitriptan) orally disintegrating tablets
2.5 mg
Teva Standard
Migraine Therapy
5-HT
1
Receptor Agonist
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
M1B 2K9
www.tevacanada.com
Submission Control No: 237687
Date of Revision:
April 6, 2020
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
4
ADVERSE REACTIONS
.........................................................................................................
12
DRUG INTERACTIONS
.........................................................................................................
18
DOSAGE AND ADMINISTRATION
.....................................................................................
19
OVERDOSAGE
.......................................................................................................................
21
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 21
STORAGE AND STABILITY
.................................................................................................
24
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 24
PART II: SCIENTIFIC INFORMATION
...............................................................................
25
PHARMACEUTICAL INFORMATION
.................................................................................
25
CLINICAL TRIALS
...........................................
阅读完整的文件
